In patients with moderate to severe atopic dermatitis, nemolizumab demonstrated good durability of response, explained Jonathan Silverberg, MD, PhD, MPH, FAAD, of George Washington University School of Medicine and Health Sciences.
This content was produced independently by The American Journal of Managed Care® and is not endorsed by the American Academy of Dermatology.
The results of this study demonstrated good durability of response and even some ongoing improvement with nemolizumab beyond week 16 up to week 48 in patients with moderate to severe atopic dermatitis (AD), says Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences.
Transcript
Can you provide an overview of the study and the primary efficacy end points achieved at week 48 in both ARCADIA-1 and ARCADIA-2 studies for patients with moderate to severe AD receiving nemolizumab?
The late-breaking presentation was for data from ARCADIA-1 and ARCADIA-2. These are 2 global, phase 3 randomized control trials that included both adolescents and adults with moderate to severe atopic dermatitis. And the primary efficacy end points and readouts were presented a few months ago at the European Academy of Dermatology and Venereology, which is that initial 16-week treatment period where patients were given either nemolizumab or the placebo.
This late-breaking presentation examined the 32-week maintenance data from these 2 studies. Patients who are responders by either IGA [Investigator Global Assessment] score or EASI [Eczema Are and Severity Index] 75 response to nemolizumab at week 16, we then re-randomized to get ongoing nemolizumab every 4 weeks, a maintenance dose of every 8 weeks, or placebo at every 4-week intervals for another 32 weeks. And all this is in the background of using topical prescription, topical therapy, corticosteroids, or calcineurin inhibitors.
And what we found was that at week 48, so 32 weeks after that 16-week initial read out, that a very high proportion of patients who are responders maintained that response, really on all doses, whether it was the ongoing every 4-week dose or the every 8-week dose, and even for many who were getting the placebo. And that was true whether it was for IGA responses getting to clear/almost clear, EASI 75 responses, 4-point reduction in itch, as well as even sleep responses and quality of life and things like that. So, we're really seeing good durability of response. Even for some of the end points [there’s] a little bit of an ongoing gain of response beyond week 16 out to that week 48 period.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More